Therapeutic Classification: antineoplastics
Pharmacologic Classification: heavy metals
Absorption: IV administration results in complete bioavailability.
Distribution: Arsenic is stored in liver, kidney, heart, lung, hair, and nails.
Metabolism/Excretion: Converted from pentavalent arsenic to trivalent arsenic by arsenate reductase and further converted by methyltransferases in the liver. Methylated arsenic is excreted in urine.
Half-Life: Unknown.
(effect on hematologic parameters)
| ROUTE | ONSET | PEAK | DURATION |
|---|
| IV | unknown | unknown | unknown |
Newly Diagnosed Low-Risk APL
- IV (Adults ): Induction: 0.15 mg/kg once daily until bone marrow remission (not to exceed 60 doses); Consolidation: 0.15 mg/kg once daily 5 days per wk during Wk 1–4 of an 8-wk cycle, for a total of 4 cycles.
Relapsed or Refractory APL
- IV (Adults and Children ≥5 yr): Induction: 0.15 mg/kg once daily until bone marrow remission (not to exceed 60 doses); Consolidation (starting 3–6 wk after completion of induction): 0.15 mg/kg once daily for 25 doses over a period of 5 wk.